In Vitro Studies Indicate that Miquelianin (Quercetin 3-O-ß-D-Glucuronopyranoside) is Able to Reach the CNS from the Small Intestine

Abstract

Miquelianin (quercetin 3-O-ß-D-glucuronopyranoside) is one of the flavonoids of St. John’s wort (Hypericum perforatum L.) whose antidepressant activity has been shown by the forced swimming test, an in vivo pharmacological model with rats. However, nothing is known about its ability to reach the CNS after oral administration. We examined the pathway of miquelianin from the small intestine to the central nervous system using three in vitro membrane barrier cell systems. In the Caco-2 cell line, miquelianin showed a higher uptake (1.93 ± 0.9 pmol × min^-1 × cm^-2) than hyperoside (quercetin 3-O-ß-D-galactopyranoside; 0.55 ± 0.18 pmol × min^-1 × cm^-2) and quercitrin (quercetin 3-O-α-L-rhamnopyranoside; 0.22 ± 0.08 pmol × min^-1 × cm^-2). The permeability coefficient of miquelianin (P _c = 0.4 ± 0.19 × 10 ^{- 6} cm/sec) was in the range of orally available drugs assuming sufficient absorption from the small intestine. Uptake and permeability of the examined compounds was increased by the MRP-2 inhibitor MK-571 indicating a backwards transport by this membrane protein. Porcine cell cultures of brain capillary endothelial cells were used as a model of the blood-brain barrier (bbb) and epithelial cells of the plexus chorioidei as a model of the blood-CSF barrier (bcb). Results indicate no active transport in one direction. Although moderate, the permeability coefficients (bbb: P _c = 1.34 ± 0.05 × 10 ^{- 6} cm/sec; bcb: P _c = 2.0 ± 0.33 × 10 ^{- 6} cm/sec) indicate the ability of miquelianin to cross both barriers to finally reach the CNS.

Key words

Caco-2 cells - blood-brain barrier - blood-CSF barrier - flavonol glycosides - miquelianin - St. John’s wort - Hypericum perforatum - Clusiaceae

References

• 1 Schulz V. Klinische Studien mit Hypericum-Extrakten bei Patienten mit Depressionen.  Z Phytother. 2002;  23 11-5
• 2 Nahrstedt A. Antidepressant constituents of Hypericum perforatum . In: Chrubasik S, Roufogalis BD, editors Herbal medicinal products for the treatment of pain. Lismore NSW; Southern Cross University Press 2000: pp. 144-53
• 3 Butterweck V, Christoffel V, Nahrstedt A, Petereit F, Spengler B, Winterhoff H. Step by step removal of hyperforin and hypericin: Activity profile of different Hypericum preparations in behavioural models.  Life Sciences. 2003;  73 627-39
• 4 Butterweck V, Juergenliemk G, Nahrstedt A, Winterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test.  Planta Med. 1999;  66 3-6
• 5 Gee J M, Dupont M S, Day A J, Plumb G W, Williamson G, Johnson I T. Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway.  J Nutr. 2000;  130 2765-71
• 6 Graefe E U, Wittig J, Mueller S, Riethling A K, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H, Veit M. Pharmacokinetics and bioavailability of quercetin glycosides in humans.  Herbal Med. 2001;  41 492-9
• 7 Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.  Biochem Biophys Res Commun. 1991;  175 880-5
• 8 Franke H, Galla H J, Beuckmann C T. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro .  Brain Res Prot. 2000;  5 248-56
• 9 Gath U, Hakvoort A, Wegener J, Decker S, Galla H J. Porcine choroid plexus cells in culture: expression of polarized phenotype, maintenance of barrier properties and apical secretion of CSF-components.  Europ J Cell Biol. 1997;  74 68-78
• 10 Juergenliemk G, Nahrstedt A. Phenolic compounds from Hypericum perforatum L.  Planta Med. 2002;  68 88-91
• 11 Boje K. Phytochemische und biopharmazeutische Untersuchungen an Harpagophytum procumbens DC. PhD Thesis 2002 Münster, Germany;
• 12 Tewes B, Galla H J. Lipid polarity in brain capillary endothelial cells.  Endothelium. 2001;  8 207-20
• 13 Wegener J, Hakvoort A, Galla H J. Barrier function of porcine choroid plexus epithelial cells is modulated by cAMP-dependent pathways in vitro .  Brain Res. 2000;  853 115-24
• 14 Artursson P, Karlsson J, Ocklind G, Schipper N. Studying transport process in absortive epithelia. In: Shaw AJ Epithelia cell culture - a practical approach. RL Press 1996: pp. 111-33
• 15 Walgren R A, Lin J T, Kinne R KH, Walle T. Cellular uptake of dietary flavonoid quercetin-4′-ß-glucoside by sodium-dependent glucose transporter SGLT1.  J Pharmacol Exp Ther. 2000;  294 837-43
• 16 Walgren R A, Karnaky K J, Lindenmayer G E, Walle T. Efflux of dietary flavonoid quercetin-4′-ß-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2.  J Pharmacol Exp Ther. 2000;  294 830-6
• 17 Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth.  Pharm Res. 1997;  14 763-6
• 18 Tantishaiyakul V. Prediction of Caco-2 cell permeability using partial least squares multivariate analysis.  Pharmazie. 2001;  56 407-11
• 19 Walgren R A, Walle U K, Walle T. Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells.  Biochem Pharmacol. 1998;  55 1721-7
• 20 Engelbertz C, Korte D, Nitz T, Franke H, Haselbach M, Wegener J, Galla H J. The development of in vitro models for the blood brain and blood-CSF barriers. In: Begley DJ, Bradbury MW, Kreuter, J. editors The Blood-Brain Barrier and Drug Delivery to the CNS. New York, Basel; Marcel Dekker, Inc 2000: pp. 33-63
• 21 Lohmann C, Huewel S, Galla H J. Predicting blood-brain barrier permeability of drugs: Evaluation of different in vitro assays.  J Drug Targ. 2002;  10 263-76
• 22 Haselbach M. Die Blut-Liquor-Schranke in vitro: Charakterisierung von Barrierefunktion und Transportvorgängen. PhD Thesis 2000 Münster, Germany;